Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
Consumer OTC Drugs

Aleve Sales Still Hit By NSAID Publicity; Roche Integration On Track – Bayer

This article was originally published in The Tan Sheet

  • News
  • The Tan Sheet

Executive Summary

Sales of Aleve (naproxen sodium) continued to suffer during the second quarter due to NSAID class safety concerns, Bayer reported during an Aug. 10 earnings call from Leverkusen, Germany

You may also be interested in...



Bayer Healthcare Sales, Schering Acquisition Drive Third Quarter Gains

Sales of Aleve pain reliever continue to recover from revenue dips resulting from NSAID safety concerns, increasing 21.6% to $81.2 mil. in the third-quarter (ended Sept. 30), Bayer announced Nov. 27

Bayer Healthcare Sales, Schering Acquisition Drive Third Quarter Gains

Sales of Aleve pain reliever continue to recover from revenue dips resulting from NSAID safety concerns, increasing 21.6% to $81.2 mil. in the third-quarter (ended Sept. 30), Bayer announced Nov. 27

Bayer Healthcare Sales, Schering Acquisition Drive Third Quarter Gains

Sales of Aleve pain reliever continue to recover from revenue dips resulting from NSAID safety concerns, increasing 21.6% to $81.2 mil. in the third-quarter (ended Sept. 30), Bayer announced Nov. 27
Table

View full table

Related Content

Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet Pink Sheet

Topics

Tags:
Consumer OTC Drugs
UsernamePublicRestriction

Register

PS098523

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By